GenScript COVID-19 virus antigens and antibodies

Thursday, 23 September, 2021 | Supplied by: GenScript Biotech (Singapore) Pte Ltd


From diagnostics to drug discovery and vaccine development, GenScript has developed a comprehensive range of products that scientists may use to accelerate COVID-19 research and development. As the virus continues to mutate, much focus is now being placed on the variants due to their more infectious nature. GenScript provides both wild-type and variant versions (eg, Alpha, Beta, Gamma, Delta, Lambda, etc) of the SARS-CoV-2 protein, and these have been validated to bind to the human ACE2 receptor and may serve as antigens in both ELISA assays and Western Blot.

To complement these antigens, the company also offers COVID-19 antibodies that are specific to the SARS-CoV-2 nucleocapsid protein or the SARS-CoV-2 spike protein. The SARS-CoV-2 Spike Neutralizing Antibody Standard (A02087) is particularly useful in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 neutralising antibodies. Neutralising antibodies are known to be more effective than regular binding antibodies in decreasing the SARS-CoV-2 viral infection of cells. The antibody standard binds to multiple neutralising epitopes in the receptor binding domain, and may be used in ELISA assays and in performing neutralisation tests.

Online: www.genscript.com
Phone: +65 649 15073
Related Products

Bioss In Vivo Biosimilar Antibodies

Bioss In Vivo Biosimilar Antibodies are research-grade copies of therapeutic antibodies that are...

LSBio virology research products

LSBio offers antibodies, proteins, ELISA kits, assay kits and chemical compounds used by...

Beckman Coulter Life Sciences IR820 and IR870 infrared dye antibody conjugates

The products provide research flow cytometry labs with a low-noise solution, including single...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd